AstraZeneca’s Saphnelo (anifrolumab) has been approved in the European Union (EU) for subcutaneous self-administration as a pre-filled pen for adult patients with systemic lupus erythematosus (SLE) on top of standard therapy.
Atelerix, a biotech company revolutionising cell preservation and biological transport with its pioneering hydrogel encapsulation technology, has entered a partnership with Cherry Biotech.
Particology, a particle science company based at science and business hub Discovery Park, has been selected for an £8.2M Government-funded research consortium to make the manufacture of medicines more efficient and sustainable.
SteriPack, a global contract design and manufacturing organisation (CDMO) for the pharmaceutical and medical device industries, has announced its trading name change to Ensera, signalling a strategic shift in its identity and service offering.
Gaelic Laboratories, a manufacturer of Beta-Lactam (penicillin) products, has announced its acquisition of Athlone Laboratories, a developer and manufacturer of oral dose Beta-Lactams.
Avantor has announced the launch of its pre-engineered PUPSIT (pre-use, post-sterilisation integrity testing) assemblies and comprehensive sterile sampling suite.
Covestro has announced the closing of its strategic partnership with XRG P.J.S.C. (formerly ADNOC International Limited, together with its subsidiaries in the following “XRG”).
Cellular Origins, a TTP company that enables the manufacturing of cell therapies at scale, has announced the completion of a $40 million over-subscribed Series A round.
Phillips Medisize, a Molex company, will showcase its inhaled drug delivery device and formulation platforms and capabilities at the Drug Delivery to the Lungs conference (DDL 2025) in Edinburgh, Scotland, 10-12th December.
Cell and Gene Therapy Catapult (CGT Catapult) has established a consortium to demonstrate how safety tests that detect potentially dangerous undifferentiated residual cells, which can affect product purity, could be applied to cell therapies.
